eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 16
Letter to the Editor

Expression of markers of neural stem and progenitor cells in glioblastoma multiforme in relation to tumor recurrence and overall survival

Paweł Wańkowicz
Dorota Rogińska
Bogusław Machaliński
Przemysław Nowacki

Arch Med Sci 2020; 16 (2): 481–483
Online publish date: 2020/02/04
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
In the current classification of the World Health Organization, gliomas are classified into four grades (G1–4). The most malignant in this group of central nervous syndrome (CNS) tumors is glioblastoma multiforme (GBM), constituting 12–15% of all brain tumors. Despite advances in neurosurgery, radiation and chemotherapy, the average survival rate is only 12.1 months in the application of radiotherapy or 14.6 months for additional therapy with temozolomide [1]. The previous decade has been a period of particular interest in cancer stem cells, identified in a variety of primary tumors – for example in cancers of the colon, lungs, and in some hemato-oncological diseases, e.g. chronic myeloid leukemia [2, 3]. Stem cells in GBM may be isolated from other cells in the primary tumor of the brain with the use of markers of neural stem cells, i.e. CD133, nestin, βIII-tubulin, as well as markers of glial cells, for example GFAP. Currently, it is being suggested that transcription factors such as Nanog, Oct-4, Rex and Olig2 can be used as biomarkers of cancer stem cells and help identify these cells in a tumor [4–6]. Although we know a number of stem cell markers, including GBM cell markers, much less is known about the behavior of those cells under the influence of radiation and chemotherapy, and their effect on tumor recurrence and overall survival. Moreover, the results of individual studies tend to be divergent. Some authors argue that the expression of markers of stem cells/progenitor cells in GBM is an unfavorable prognostic marker [7]. Other researchers disagree [8]. Therefore, the aim of the present work was to evaluate the relationship between expression of markers of stem/progenitor cells in the tumor and the time to tumor recurrence and the survival of patients with GBM. The study involved material containing cancer tissue collected during routine neurosurgical treatment of 21 patients of both genders (10 women, 11 men) aged 30 to 77 years (median 56 years). The study protocol did not include another procedure during surgery or collection of more material than necessary for tumor removal. Nervous tissue comprising cancer tissue was frozen directly after removal in liquid nitrogen at –80°C. Once the diagnosis was confirmed by histopathological examination, detection of stem/progenitor cells was performed using molecular assessment. Patients were divided into groups according to the results of analysis in which the expression of markers of...

View full text...
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe